Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand

Pochamana Phisalprapa; Chayanis Kositamongkol; Julajak Limsrivilai; Satimai Aniwan; Phunchai Charatcharoenwitthaya; Pises Pisespongsa; Taya Kitiyakara; Suporn Treepongkaruna; Nathorn Chaiyakunapruk

doi:10.1080/13696998.2020.1803889

Cost-effectiveness and budget impact analysis of infliximab and its biosimilar in patients with refractory moderate-to-severe Crohn’s disease using real world evidence in Thailand

Journal of Medical Economics ◽

10.1080/13696998.2020.1803889 ◽

2020 ◽

Vol 23 (11) ◽

pp. 1302-1310

Author(s):

Pochamana Phisalprapa ◽

Chayanis Kositamongkol ◽

Julajak Limsrivilai ◽

Satimai Aniwan ◽

Phunchai Charatcharoenwitthaya ◽

...

Keyword(s):

Crohn’S Disease ◽

Cost Effectiveness ◽

Crohn's Disease ◽

Real World ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Real World Evidence

Download Full-text

P137. 5 year budget impact analysis of CT-P13 (Infliximab) for the treatment of Crohn's Disease in UK, Italy and France

Journal of Crohn s and Colitis ◽

10.1093/ecco-jcc/jju027.254 ◽

2015 ◽

Vol 9 (suppl 1) ◽

pp. S144-S145 ◽

Cited By ~ 6

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis

Download Full-text

Budget Impact Analysis Of Biosimilar Infliximab For The Treatment Of Crohn's Disease In Six Central Eastern European Countries

Value in Health ◽

10.1016/j.jval.2014.08.805 ◽

2014 ◽

Vol 17 (7) ◽

pp. A364 ◽

Cited By ~ 4

Author(s):

V. Brodszky ◽

L. Gulacsi ◽

O. Balogh ◽

P Baji ◽

F. Rencz ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

European Countries ◽

Eastern European ◽

Central Eastern ◽

Eastern European Countries

Download Full-text

Budget impact analysis of medicines: estimated values versus real-world evidence and the implications

Expert Review of Pharmacoeconomics & Outcomes Research ◽

10.1080/14737167.2021.1927716 ◽

2021 ◽

Author(s):

Daniel Resende Faleiros ◽

Juliana Alvares-Teodoro ◽

Everton Nunes da Silva ◽

Brian B. Godman ◽

Ramon Gonçalves Pereira ◽

...

Keyword(s):

Real World ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Real World Evidence

Download Full-text

FIVE YEAR BUDGET IMPACT ANALYSIS OF BIOSIMILAR INFLIXIMAB (CT-P13) FOR THE TREATMENT OF CROHN'S DISEASE AND ULCERATIVE COLITIS IN SPAIN

10.26226/morressier.57c5383cd462b80296c9b833 ◽

2016 ◽

Author(s):

Seong-Hee Han

Keyword(s):

Ulcerative Colitis ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis

Download Full-text

Budget Impact Analysis of Ustekinumab for the Treatment of Moderate to Severe Crohn’s Disease from a Brazilian Private Payer Perspective

Value in Health ◽

10.1016/j.jval.2018.04.559 ◽

2018 ◽

Vol 21 ◽

pp. S82

Author(s):

CO Fioratti ◽

E Asano ◽

RP Rosim

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Payer Perspective ◽

Private Payer

Download Full-text

Cost-minimization and budget impact analysis of certolizumab pegol for patients with Crohn’s disease, moderate or severe, with relapse after conventional treatment from the perspective of the Brazilian private payer

Jornal Brasileiro de Economia da Saúde ◽

10.21115/jbes.v9.n1.p44-53 ◽

2017 ◽

Vol 9 (1) ◽

pp. 44-53

Author(s):

Ricardo Rosim ◽

Andreas Duva ◽

André Ferraz ◽

Arcangela Valle ◽

Emese Tóth ◽

...

Keyword(s):

Crohn’S Disease ◽

Crohn's Disease ◽

Conventional Treatment ◽

Impact Analysis ◽

Budget Impact ◽

Cost Minimization ◽

Certolizumab Pegol ◽

Budget Impact Analysis ◽

Private Payer

Download Full-text

A Five Years Budget Impact Analysis of The Introduction of Adalimumab For Crohn’s Disease Patients From The Perspective of The Brazilian Private Health Care System

Value in Health ◽

10.1016/j.jval.2015.09.2410 ◽

2015 ◽

Vol 18 (7) ◽

pp. A663

Author(s):

FG Menezes ◽

V Chibana

Keyword(s):

Health Care ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Health Care System ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Private Health Care ◽

Care System

Download Full-text

BIOLOGICAL THERAPY IN ADULT PATIENTS WITH ULCERATIVE COLITIS AND CROHN’S DISEASE: BUDGET IMPACT ANALYSIS

PHARMACOECONOMICS Modern pharmacoeconomics and pharmacoepidemiology ◽

10.17749/2070-4909.2017.10.1.019-028 ◽

2017 ◽

Vol 10 (1) ◽

pp. 19-28

Author(s):

E. A. Pyadushkina

Keyword(s):

Ulcerative Colitis ◽

Crohn’S Disease ◽

Crohn's Disease ◽

Impact Analysis ◽

Budget Impact ◽

Biological Therapy ◽

Budget Impact Analysis ◽

Adult Patients

Download Full-text

Budget Impact Analysis of Atypical Long-Acting Anti-Psychotics in Sweden Using Real-World Evidence from the Swedish Prescritpion Registry

Value in Health ◽

10.1016/j.jval.2018.07.568 ◽

2018 ◽

Vol 21 ◽

pp. S75-S76

Author(s):

JG Lundberg ◽

E Gustafsson ◽

A Berntsson

Keyword(s):

Real World ◽

Impact Analysis ◽

Budget Impact ◽

Budget Impact Analysis ◽

Real World Evidence ◽

Long Acting

Download Full-text

Cost-utility Analysis, Cost-effectiveness Analysis, Budget Impact Analysis

Case Medical Research ◽

10.31525/ct1-nct04283565 ◽

2020 ◽

Author(s):

Keyword(s):

Cost Effectiveness ◽

Impact Analysis ◽

Budget Impact ◽

Cost Utility ◽

Cost Effectiveness Analysis ◽

Cost Utility Analysis ◽

Budget Impact Analysis ◽

Utility Analysis ◽

Effectiveness Analysis

Download Full-text